Geun Dong Lee1, Hyeong Ryul Kim1, Se Hoon Choi1, Yong-Hee Kim1, Dong Kwan Kim1, Seung-Il Park1. 1. 1 Department of Thoracic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea ; 2 Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: The aims of this study were to stratify the risk of recurrence based on the Masaoka-Koga stage and World Health Organization (WHO) classification systems after R0-resection for thymic epithelial tumors (TETs). METHODS: A retrospective analysis was conducted on 479 patients who underwent surgery between Jan 1994 and Feb 2014 for TETs. The study group comprised 251 males and 228 females, with a median age of 52 years (range, 15-84 years). RESULTS: Of the 479 patients, 406 (84.8%) patients underwent R0-resection. Recurrence after R0-resection occurred in 32 patients during a median follow-up of 53 months (range, 2-227 months). A multivariate analysis revealed that the preoperative treatment including chemotherapy (P=0.036), Masaoka-Koga stage (P=0.011) and the WHO classification (P=0.001) were predictors for recurrence after R0-resection. Patients were stratified into four risk groups using a potential model incorporating both the Masaoka-Koga stage and WHO classifications. Group 1 comprised WHO types A/AB/B1 in stage I/II; Group 2 comprised WHO type A/AB/B1 in stage III or WHO type B2/B3 in stage I/II or WHO type C in stage I; Group 3 comprised Type B2/B3/C in stage III, or WHO type C in stage II/III; and Group 4 comprised WHO type B2/B3/C in stage IV. The 5-year freedom-from-recurrence (FFR) rates were 99.4% for group 1, 84.7% for group 2, 63.7% for group 3, and less than 44.4% for group 4 (P<0.001). In group 3, the rate of locoregional recurrence of patients treated with postoperative radiation therapy was lower than patients treated without postoperative radiation therapy (P=0.032). CONCLUSIONS: A risk model incorporating both Masaoka-Koga stage and WHO classification systems may provide multi-faceted information about recurrence and adjuvant treatment after R0-resection of TETs.
BACKGROUND: The aims of this study were to stratify the risk of recurrence based on the Masaoka-Koga stage and World Health Organization (WHO) classification systems after R0-resection for thymic epithelial tumors (TETs). METHODS: A retrospective analysis was conducted on 479 patients who underwent surgery between Jan 1994 and Feb 2014 for TETs. The study group comprised 251 males and 228 females, with a median age of 52 years (range, 15-84 years). RESULTS: Of the 479 patients, 406 (84.8%) patients underwent R0-resection. Recurrence after R0-resection occurred in 32 patients during a median follow-up of 53 months (range, 2-227 months). A multivariate analysis revealed that the preoperative treatment including chemotherapy (P=0.036), Masaoka-Koga stage (P=0.011) and the WHO classification (P=0.001) were predictors for recurrence after R0-resection. Patients were stratified into four risk groups using a potential model incorporating both the Masaoka-Koga stage and WHO classifications. Group 1 comprised WHO types A/AB/B1 in stage I/II; Group 2 comprised WHO type A/AB/B1 in stage III or WHO type B2/B3 in stage I/II or WHO type C in stage I; Group 3 comprised Type B2/B3/C in stage III, or WHO type C in stage II/III; and Group 4 comprised WHO type B2/B3/C in stage IV. The 5-year freedom-from-recurrence (FFR) rates were 99.4% for group 1, 84.7% for group 2, 63.7% for group 3, and less than 44.4% for group 4 (P<0.001). In group 3, the rate of locoregional recurrence of patients treated with postoperative radiation therapy was lower than patients treated without postoperative radiation therapy (P=0.032). CONCLUSIONS: A risk model incorporating both Masaoka-Koga stage and WHO classification systems may provide multi-faceted information about recurrence and adjuvant treatment after R0-resection of TETs.
Authors: Frank C Detterbeck; Kelly Stratton; Dorothy Giroux; Hisao Asamura; John Crowley; Conrad Falkson; Pier Luigi Filosso; Aletta A Frazier; Giuseppe Giaccone; James Huang; Jhingook Kim; Kazuya Kondo; Marco Lucchi; Mirella Marino; Edith M Marom; Andrew G Nicholson; Meinoshin Okumura; Enrico Ruffini; Paul Van Schil Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Cameron D Wright; John C Wain; Daniel R Wong; Dean M Donahue; Henning A Gaissert; Hermes C Grillo; Douglas J Mathisen Journal: J Thorac Cardiovasc Surg Date: 2005-10-13 Impact factor: 5.209
Authors: Frank C Detterbeck; Hisao Asamura; John Crowley; Conrad Falkson; Giuseppe Giaccone; Dori Giroux; James Huang; Jhingook Kim; Kazuya Kondo; Marco Lucchi; Mirella Marino; Edith M Marom; Andrew Nicholson; Meinoshin Okumura; Enrico Ruffini; Paul van Schil; Kelly Stratton Journal: J Thorac Oncol Date: 2013-12 Impact factor: 15.609
Authors: Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Sunil Singhal; Joseph B Shrager; David I Rosenthal; Virginia A LiVolsi; Larry R Kaiser Journal: Ann Thorac Surg Date: 2003-11 Impact factor: 4.330
Authors: Jordan Bakhriansyah; I Gede Parama Gandi Semita; I Gde Rurus Suryawan; Yusuf Azmi; Irfan Deny Sanjaya; Risma Ikawaty; David Nugraha; Firas Farisi Alkaff Journal: Radiol Case Rep Date: 2022-08-17